US5831002A
(en)
|
1992-05-20 |
1998-11-03 |
Basf Aktiengesellschaft |
Antitumor peptides
|
US5861297A
(en)
|
1996-09-27 |
1999-01-19 |
Merck & Co., Inc. |
Detergent-free hepatitis C protease
|
JP4354632B2
(ja)
|
1997-08-11 |
2009-10-28 |
ベーリンガー インゲルハイム (カナダ) リミテッド |
C型肝炎抑制剤ペプチド
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
US20040058982A1
(en)
*
|
1999-02-17 |
2004-03-25 |
Bioavailability System, Llc |
Pharmaceutical compositions
|
JP4690545B2
(ja)
|
1998-03-31 |
2011-06-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
|
AR022061A1
(es)
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
US6608027B1
(en)
*
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
WO2001040262A1
(en)
|
1999-12-03 |
2001-06-07 |
Bristol-Myers Squibb Pharma Company |
Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
|
CA2396504A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Dupont Pharmaceuticals Company |
Inhibitors of hepatitis c virus ns3 protease
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6846806B2
(en)
*
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
ES2263687T3
(es)
|
2000-11-20 |
2006-12-16 |
Bristol-Myers Squibb Company |
Inhibidores tripeptidicos de la hepatitis c.
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
US6727366B2
(en)
*
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
FR2821272B1
(fr)
|
2001-02-23 |
2004-12-17 |
Synt Em |
Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
|
WO2003025563A1
(en)
|
2001-09-16 |
2003-03-27 |
Chemometec A/S |
Method and a system for detecting and optionally isolating a rare event particle
|
EP1429759A4
(en)
|
2001-09-26 |
2004-12-15 |
Bristol Myers Squibb Co |
COMPOUNDS FOR TREATING HEPATITIS C VIRUS
|
US6867185B2
(en)
*
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
CA2369711A1
(en)
|
2002-01-30 |
2003-07-30 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis c virus
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6828301B2
(en)
|
2002-02-07 |
2004-12-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2004032827A2
(en)
*
|
2002-05-20 |
2004-04-22 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
ATE413411T1
(de)
*
|
2002-05-20 |
2008-11-15 |
Bristol Myers Squibb Co |
Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
|
DE60334205D1
(en)
*
|
2002-05-20 |
2010-10-28 |
Bristol Myers Squibb Co |
Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
|
US20060199773A1
(en)
|
2002-05-20 |
2006-09-07 |
Sausker Justin B |
Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
|
US20030232386A1
(en)
|
2002-06-17 |
2003-12-18 |
Shah Dinesh O. |
Assay conjugate and uses thereof
|
US7037911B2
(en)
*
|
2002-06-26 |
2006-05-02 |
Bristol-Myers Squibb Company |
Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors
|
AU2003261434A1
(en)
*
|
2002-08-12 |
2004-02-25 |
Bristol-Myers Squibb Company |
Iminothiazolidinones as inhibitors of hcv replication
|
US20040138109A1
(en)
|
2002-09-30 |
2004-07-15 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Potent inhibitor of HCV serine protease
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US20050159345A1
(en)
|
2002-10-29 |
2005-07-21 |
Boehringer Ingelheim International Gmbh |
Composition for the treatment of infection by Flaviviridae viruses
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
JP2007524576A
(ja)
*
|
2003-02-07 |
2007-08-30 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
大環状のc型肝炎セリンプロテアーゼ阻害剤
|
US20040180815A1
(en)
|
2003-03-07 |
2004-09-16 |
Suanne Nakajima |
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
|
CA2516016C
(en)
|
2003-03-05 |
2012-05-29 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibiting compounds
|
UY28240A1
(es)
|
2003-03-27 |
2004-11-08 |
Boehringer Ingelheim Pharma |
Fases cristalinas de un potente inhibidor de la hcv
|
EP1613353A1
(en)
|
2003-04-02 |
2006-01-11 |
Boehringer Ingelheim International GmbH |
Pharmaceutical compositions for hepatitis c viral protease inhibitors
|
CA2521835A1
(en)
|
2003-04-10 |
2004-10-21 |
Boehringer Ingelheim International Gmbh |
Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
|
WO2004092203A2
(en)
|
2003-04-10 |
2004-10-28 |
Boehringer Ingelheim International, Gmbh |
Process for preparing macrocyclic compounds
|
ES2386161T3
(es)
|
2003-04-16 |
2012-08-10 |
Bristol-Myers Squibb Company |
Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
|
US7176208B2
(en)
*
|
2003-04-18 |
2007-02-13 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
|
SI1615613T1
(sl)
*
|
2003-04-18 |
2010-03-31 |
Enanta Pharm Inc |
Kinoksalinilni makrociklični inhibitorji serinske proteaze hepatitisa C
|
ES2297424T3
(es)
|
2003-05-21 |
2008-05-01 |
Boehringer Ingelheim International Gmbh |
Compuestos inhibidores de la hepatitis c.
|
US7273851B2
(en)
|
2003-06-05 |
2007-09-25 |
Enanta Pharmaceuticals, Inc. |
Tri-peptide hepatitis C serine protease inhibitors
|
US7112601B2
(en)
|
2003-09-11 |
2006-09-26 |
Bristol-Myers Squibb Company |
Cycloalkyl heterocycles for treating hepatitis C virus
|
BRPI0414571A
(pt)
|
2003-09-22 |
2006-11-07 |
Boehringer Ingelheim Int |
peptìdeos macrocìclicos ativos contra o vìrus da hepatite c
|
BRPI0414814A
(pt)
|
2003-09-26 |
2006-11-14 |
Schering Corp |
inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
|
US7491794B2
(en)
*
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
JP4584260B2
(ja)
|
2003-10-14 |
2010-11-17 |
インターミューン・インコーポレーテッド |
Hcv複製阻害剤としての大環状カルボン酸およびアシルスルホンアミド
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7253160B2
(en)
|
2003-11-20 |
2007-08-07 |
Schering Corporation |
Depeptidized inhibitors of hepatitis C virus NS3 protease
|
FR2863268B1
(fr)
|
2003-12-09 |
2006-02-24 |
Sod Conseils Rech Applic |
Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
|
EP1742913A1
(en)
|
2003-12-11 |
2007-01-17 |
Schering Corporation |
Inhibitors of hepatitis c virus ns3/ns4a serine protease
|
CA2549851C
(en)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis c virus
|
ES2315839T3
(es)
|
2004-01-28 |
2009-04-01 |
Boehringer Ingelheim International Gmbh |
Metodo para separar los metales de transicion de soluciones reaccionantes que contienen productos secundarios de metales de transicion.
|
DE602005017582D1
(en)
|
2004-01-30 |
2009-12-24 |
Medivir Ab |
Hcv ns-3 serine protease inhibitoren
|
JP4654239B2
(ja)
|
2004-03-15 |
2011-03-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法
|
CA2560897C
(en)
|
2004-03-30 |
2012-06-12 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
JP5156374B2
(ja)
|
2004-05-25 |
2013-03-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
非環式hcvプロテアーゼインヒビターの調製方法
|
EP1763531A4
(en)
|
2004-06-28 |
2009-07-01 |
Boehringer Ingelheim Int |
ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
|
DE102004033312A1
(de)
|
2004-07-08 |
2006-01-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
|
PL1778702T3
(pl)
*
|
2004-07-16 |
2011-12-30 |
Gilead Sciences Inc |
Związki przeciwwirusowe
|
ATE512971T1
(de)
*
|
2004-07-20 |
2011-07-15 |
Boehringer Ingelheim Int |
Peptidanaloga als hepatitis c-hemmer
|
UY29016A1
(es)
*
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
US7348425B2
(en)
*
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
WO2006033851A1
(en)
|
2004-09-17 |
2006-03-30 |
Boehringer Ingelheim International, Gmbh |
Ring-closing metathesis process in supercritical fluid
|
JP2008513454A
(ja)
*
|
2004-09-17 |
2008-05-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
大環状hcvプロテアーゼインヒビターの調製方法
|
WO2006036614A2
(en)
|
2004-09-24 |
2006-04-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
|
WO2007001406A2
(en)
*
|
2004-10-05 |
2007-01-04 |
Chiron Corporation |
Aryl-containing macrocyclic compounds
|
US20090036708A1
(en)
*
|
2004-10-14 |
2009-02-05 |
Lanqi Jia |
Novel Process for the Preparation of Nonracemic Long Chain alpha-Amino Acid Derivatives
|
JP2008517896A
(ja)
|
2004-10-21 |
2008-05-29 |
ファイザー・インク |
C型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
|
US7323447B2
(en)
*
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
DK1863833T3
(da)
|
2005-03-08 |
2013-12-02 |
Boehringer Ingelheim Int |
Fremgangsmåde til fremstilling af makrocykliske forbindelser
|
CN101163404A
(zh)
|
2005-04-25 |
2008-04-16 |
巴斯福股份公司 |
5-烷基-6-苯基烷基-7-氨基唑并嘧啶的用途、新的唑并嘧啶、其制备方法以及包含它们的组合物
|
AU2006242475B2
(en)
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2006128455A2
(en)
|
2005-05-25 |
2006-12-07 |
2Curex Aps |
Compounds modifying apoptosis
|
US20060276404A1
(en)
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
US20070004635A1
(en)
*
|
2005-06-02 |
2007-01-04 |
Schering Corporation |
Method of treating interferon non-responders using HCV protease inhibitor
|
US20060276406A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
CA2611145A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation useful for treating disorders associated with hepatitis c virus
|
US20070237818A1
(en)
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
WO2006130688A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Compounds for inhibiting cathepsin activity
|
US20060275366A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
KR20080021634A
(ko)
*
|
2005-06-02 |
2008-03-07 |
쉐링 코포레이션 |
약제학적 조성물 및 이를 사용한 치료 방법
|
US20060276407A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
US20070021351A1
(en)
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
WO2006130627A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods for treating hepatitis c
|
WO2006130626A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
|
PL1891089T3
(pl)
|
2005-06-02 |
2015-05-29 |
Merck Sharp & Dohme |
Inhibitory proteazy HCV w połączeniu z pokarmem
|
US7608592B2
(en)
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7632772B2
(en)
|
2005-07-04 |
2009-12-15 |
Zheng-Yun James Zhan |
Recyclable ruthenium catalysts for metathesis reactions
|
US7601686B2
(en)
*
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TW200738742A
(en)
*
|
2005-07-14 |
2007-10-16 |
Gilead Sciences Inc |
Antiviral compounds
|
TWI389908B
(zh)
|
2005-07-14 |
2013-03-21 |
Gilead Sciences Inc |
抗病毒化合物類
|
US20080200497A1
(en)
|
2005-07-20 |
2008-08-21 |
Bailey Murray D |
Hepatitis C Inhibitor Peptide Analogs
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
PE20070211A1
(es)
*
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
PT1912997E
(pt)
|
2005-07-29 |
2011-12-19 |
Tibotec Pharm Ltd |
Inibidores macrocíclicos do vírus da hepatite c
|
DK1919899T3
(da)
|
2005-07-29 |
2011-08-01 |
Tibotec Pharm Ltd |
Makrocykliske inhibitorer af hepatitis C virus
|
PE20070343A1
(es)
*
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Inhibidores macrociclicos del virus de la hepatitis c
|
EP1913015B1
(en)
|
2005-07-29 |
2013-12-11 |
Janssen R&D Ireland |
Macrocyclic inhibitors of hepatitis c virus
|
CN101273030B
(zh)
|
2005-07-29 |
2012-07-18 |
泰博特克药品有限公司 |
丙型肝炎病毒的大环抑制剂
|
CA2615896C
(en)
|
2005-08-01 |
2012-11-13 |
Merck & Co., Inc. |
Macrocyclic peptides as hcv ns3 protease inhibitors
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
JP5190364B2
(ja)
*
|
2005-09-09 |
2013-04-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
大環状ペプチドの調製の為の閉環メタセシス工程
|
US7399758B2
(en)
|
2005-09-12 |
2008-07-15 |
Meanwell Nicholas A |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
US7473688B2
(en)
*
|
2005-09-13 |
2009-01-06 |
Bristol-Myers Squibb Company |
Indolobenzazepine HCV NS5B inhibitors
|
US7723336B2
(en)
*
|
2005-09-22 |
2010-05-25 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
DK1999129T3
(da)
*
|
2005-10-11 |
2011-02-07 |
Intermune Inc |
Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
|
US7772183B2
(en)
*
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
*
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7456165B2
(en)
|
2006-02-08 |
2008-11-25 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
JP2009530382A
(ja)
|
2006-03-23 |
2009-08-27 |
シェーリング コーポレイション |
Hcvプロテアーゼインヒビターとcyp3a4インヒビターとの組み合わせ、および関連する処置方法
|
US20100018355A1
(en)
*
|
2006-05-04 |
2010-01-28 |
Crawford Ted C |
Head cap for a wrench head, wrench and method utilizing the same
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
US7521443B2
(en)
|
2006-05-17 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
US7456166B2
(en)
|
2006-05-17 |
2008-11-25 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
US7521441B2
(en)
|
2006-05-22 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
WO2007140200A2
(en)
|
2006-05-25 |
2007-12-06 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
US8268776B2
(en)
|
2006-06-06 |
2012-09-18 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
US9526769B2
(en)
|
2006-06-06 |
2016-12-27 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
US20070281884A1
(en)
|
2006-06-06 |
2007-12-06 |
Ying Sun |
Macrocyclic oximyl hepatitis C protease inhibitors
|
US7452876B2
(en)
|
2006-06-08 |
2008-11-18 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
PE20080992A1
(es)
*
|
2006-06-26 |
2008-08-06 |
Enanta Pharm Inc |
Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
|
EP2049474B1
(en)
|
2006-07-11 |
2015-11-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2008008502A1
(en)
|
2006-07-13 |
2008-01-17 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
US7635683B2
(en)
*
|
2006-08-04 |
2009-12-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl tripeptide hepatitis C virus inhibitors
|
US20090035271A1
(en)
*
|
2007-08-01 |
2009-02-05 |
Ying Sun |
Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
|
WO2008019289A2
(en)
*
|
2006-08-04 |
2008-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
|
WO2008019303A2
(en)
|
2006-08-04 |
2008-02-14 |
Enanta Pharmaceuticals, Inc. |
Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
|
WO2008022006A2
(en)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis c virus protease inhibitors
|
US20080038225A1
(en)
*
|
2006-08-11 |
2008-02-14 |
Ying Sun |
Triazolyl acyclic hepatitis c serine protease inhibitors
|
US7605126B2
(en)
*
|
2006-08-11 |
2009-10-20 |
Enanta Pharmaceuticals, Inc. |
Acylaminoheteroaryl hepatitis C virus protease inhibitors
|
US7582605B2
(en)
*
|
2006-08-11 |
2009-09-01 |
Enanta Pharmaceuticals, Inc. |
Phosphorus-containing hepatitis C serine protease inhibitors
|
WO2008021960A2
(en)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Triazolyl macrocyclic hepatitis c serine protease inhibitors
|
US7687459B2
(en)
*
|
2006-08-11 |
2010-03-30 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis C virus protease inhibitors
|
EP2068912A2
(en)
|
2006-09-27 |
2009-06-17 |
Coley Pharmaceutical Group, Inc. |
Compositions of tlr ligands and antivirals
|
US8841413B2
(en)
|
2006-10-03 |
2014-09-23 |
Cadila Healthcare Limited |
Antidiabetic compounds
|
US20120220520A1
(en)
|
2006-10-17 |
2012-08-30 |
Van T Klooster Gerben Albert Eleutherius |
Bioavailable combinations for hcv treatment
|
EP2079479B1
(en)
|
2006-10-24 |
2014-11-26 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
US8309540B2
(en)
|
2006-10-24 |
2012-11-13 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
CN101568346B
(zh)
*
|
2006-10-27 |
2015-11-25 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
KR101615500B1
(ko)
*
|
2006-10-27 |
2016-04-27 |
머크 샤프 앤드 돔 코포레이션 |
Hcv ns3 프로테아제 억제제
|
US20080107625A1
(en)
|
2006-11-01 |
2008-05-08 |
Bristol-Myers Squibb Company |
Inhibitors of Hepatitis C Virus
|
US20080107623A1
(en)
*
|
2006-11-01 |
2008-05-08 |
Bristol-Myers Squibb Company |
Inhibitors of Hepatitis C Virus
|
US8343477B2
(en)
*
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
TW200827364A
(en)
|
2006-11-02 |
2008-07-01 |
Taigen Biotechnology Co Ltd |
HCV protease inhibitors
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2661338C
(en)
|
2006-11-17 |
2015-05-12 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis c virus
|
WO2008070733A2
(en)
|
2006-12-06 |
2008-06-12 |
Phenomix Corporation |
Macrocyclic hepatitis c serine protease inhibitors and uses therefor
|
KR20090101372A
(ko)
|
2007-01-08 |
2009-09-25 |
페노믹스 코포레이션 |
매크로시클릭 c형 간염 프로테아제 억제제
|
US7541351B2
(en)
|
2007-01-11 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
WO2008095058A1
(en)
|
2007-02-01 |
2008-08-07 |
Taigen Biotechnology Co. Ltd. |
Hcv protease inhibitors
|
AU2008209696B2
(en)
|
2007-02-01 |
2013-05-09 |
Janssen Sciences Ireland Uc |
Polymorphic forms of a macrocyclic inhibitor of HCV
|
RU2481340C2
(ru)
*
|
2007-02-08 |
2013-05-10 |
Тиботек Фармасьютикалз Лтд. |
Пиримидин-замещенные макроциклические ингибиторы hcv
|
WO2008096001A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Tibotec Pharmaceuticals Ltd. |
Hcv inhibiting macrocyclic phenylcarbamates
|
US20100087382A1
(en)
|
2007-02-16 |
2010-04-08 |
Boehringer Ingelheim International Gmbh |
Inhibitors of Hepatitis C NS3 Protease
|
CN101663284A
(zh)
|
2007-02-20 |
2010-03-03 |
诺瓦提斯公司 |
作为hcv ns3蛋白酶抑制剂的大环化合物
|
EP2125113A2
(en)
|
2007-02-26 |
2009-12-02 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of hcv replication
|
ES2373616T3
(es)
|
2007-03-19 |
2012-02-07 |
Astrazeneca Ab |
Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7).
|
WO2008124384A2
(en)
|
2007-04-03 |
2008-10-16 |
Aegerion Pharmaceuticals, Inc. |
Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
|
CN101663294A
(zh)
|
2007-04-24 |
2010-03-03 |
弗·哈夫曼-拉罗切有限公司 |
Hcv蛋白酶抑制剂中间体的制备方法
|
US20080267917A1
(en)
|
2007-04-26 |
2008-10-30 |
Deqiang Niu |
N-functionalized amides as hepatitis c serine protease inhibitors
|
US8377872B2
(en)
|
2007-04-26 |
2013-02-19 |
Enanta Pharmaceuticals, Inc. |
Cyclic P3 tripeptide hepatitis C serine protease inhibitors
|
US20080279821A1
(en)
|
2007-04-26 |
2008-11-13 |
Deqiang Niu |
Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
|
US7906513B2
(en)
|
2007-04-26 |
2011-03-15 |
Enanta Pharmaceuticals, Inc. |
Hydrazide-containing hepatitis C serine protease inhibitors
|
CL2008001274A1
(es)
|
2007-05-03 |
2008-11-03 |
Intermune Inc Y Array Biopharma Inc |
Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
|
BRPI0811447A2
(pt)
|
2007-05-10 |
2014-10-29 |
Intermune Inc |
Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
|
US20090005387A1
(en)
*
|
2007-06-26 |
2009-01-01 |
Deqiang Niu |
Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
|
BRPI0813733A2
(pt)
|
2007-06-29 |
2019-11-05 |
Gilead Sciences Inc |
composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
|
WO2009005690A2
(en)
*
|
2007-06-29 |
2009-01-08 |
Gilead Sciences, Inc. |
Antiviral compounds
|
NZ582096A
(en)
|
2007-06-29 |
2012-05-25 |
Gilead Sciences Inc |
Antiviral compounds that inhibit hepatitis c virus (hcv)
|
US8927569B2
(en)
*
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
WO2009014730A1
(en)
|
2007-07-26 |
2009-01-29 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
WO2009053828A2
(en)
|
2007-10-22 |
2009-04-30 |
Enanta Pharmaceuticals, Inc. |
P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
|
US20090111757A1
(en)
*
|
2007-10-25 |
2009-04-30 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|
US8426360B2
(en)
|
2007-11-13 |
2013-04-23 |
Enanta Pharmaceuticals, Inc. |
Carbocyclic oxime hepatitis C virus serine protease inhibitors
|
EP2209789B1
(en)
|
2007-11-20 |
2011-11-16 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
US8030307B2
(en)
|
2007-11-29 |
2011-10-04 |
Enanta Pharmaceuticals, Inc. |
Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
|
US8263549B2
(en)
|
2007-11-29 |
2012-09-11 |
Enanta Pharmaceuticals, Inc. |
C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
|
CN101932242A
(zh)
*
|
2007-12-05 |
2010-12-29 |
益安药业 |
喹喔啉基衍生物
|
WO2009073713A1
(en)
|
2007-12-05 |
2009-06-11 |
Enanta Pharmaceuticals, Inc. |
Oximyl macrocyclic derivatives
|
WO2009073780A1
(en)
|
2007-12-06 |
2009-06-11 |
Enanta Pharmaceuticals, Inc. |
Process for making macrocyclic oximyl hepatitis c protease inhibitors
|
US8293705B2
(en)
*
|
2007-12-21 |
2012-10-23 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
CN101951770B
(zh)
|
2007-12-21 |
2014-12-31 |
阿维拉制药公司 |
Hcv蛋白酶抑制剂和其用途
|
US8309685B2
(en)
*
|
2007-12-21 |
2012-11-13 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
KR20150113217A
(ko)
|
2007-12-21 |
2015-10-07 |
셀진 아빌로믹스 리서치, 인코포레이티드 |
Hcv 프로테아제 억제제 및 이의 용도
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
KR101629523B1
(ko)
|
2007-12-21 |
2016-06-10 |
에프. 호프만-라 로슈 아게 |
대환 화합물의 제조방법
|
KR20100118991A
(ko)
|
2008-02-04 |
2010-11-08 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
매크로시클릭 세린 프로테아제 억제제
|
US20100081713A1
(en)
*
|
2008-03-19 |
2010-04-01 |
CombinatoRx, (Singapore) Pte. Ltd. |
Compositions and methods for treating viral infections
|
US8048862B2
(en)
|
2008-04-15 |
2011-11-01 |
Intermune, Inc. |
Macrocyclic inhibitors of hepatitis C virus replication
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20110263844A1
(en)
|
2008-05-09 |
2011-10-27 |
Boehringer Ingelheim International Gmbh |
method for preparing macrocycles
|
US20090285773A1
(en)
|
2008-05-15 |
2009-11-19 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20090285774A1
(en)
|
2008-05-15 |
2009-11-19 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CN101580535B
(zh)
|
2008-05-16 |
2012-10-03 |
太景生物科技股份有限公司 |
丙型肝炎病毒蛋白酶抑制剂
|
US8044023B2
(en)
|
2008-05-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2011522834A
(ja)
|
2008-06-05 |
2011-08-04 |
ザイモジェネティクス リミテッド ライアビリティ カンパニー |
C型肝炎の治療のためのペグ化iii型インターフェロンの使用
|
AR072428A1
(es)
|
2008-07-01 |
2010-08-25 |
Medivir Ab |
Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
|
KR101647520B1
(ko)
*
|
2008-08-07 |
2016-08-10 |
에프. 호프만-라 로슈 아게 |
거대환식 화합물의 제조 방법
|
EP2334680A2
(en)
|
2008-08-20 |
2011-06-22 |
Sequoia Pharmaceuticals, Inc. |
Hcv protease inhibitors
|
RU2014150660A
(ru)
|
2008-09-05 |
2015-07-20 |
Селджен Авиломикс Рисерч, Инк. |
Алгоритм разработки необратимо действующих ингибиторов
|
UY32099A
(es)
*
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
WO2010033466A1
(en)
|
2008-09-16 |
2010-03-25 |
Phenomix Corporation |
Macrocyclic inhibitors of hepatitis c protease
|
EP2687526A1
(en)
*
|
2008-09-16 |
2014-01-22 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
|
EP2337583A1
(en)
|
2008-09-17 |
2011-06-29 |
Boehringer Ingelheim International GmbH |
Combination of hcv ns3 protease inhibitor with interferon and ribavirin
|
US8603737B2
(en)
*
|
2008-09-19 |
2013-12-10 |
Celgene Avilomics Research, Inc. |
Methods for identifying HCV protease inhibitors
|
JP2012502925A
(ja)
|
2008-09-23 |
2012-02-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎阻害化合物
|
US20100080770A1
(en)
|
2008-09-29 |
2010-04-01 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2346329B1
(en)
|
2008-10-09 |
2013-08-21 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
WO2010048468A1
(en)
|
2008-10-23 |
2010-04-29 |
Concert Pharmaceuticals, Inc. |
Deuterated macrocyclic inhibitors of viral ns3 protease
|
US8296141B2
(en)
*
|
2008-11-19 |
2012-10-23 |
At&T Intellectual Property I, L.P. |
System and method for discriminative pronunciation modeling for voice search
|
JP5689810B2
(ja)
*
|
2008-11-20 |
2015-03-25 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
C型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
|
ES2445516T3
(es)
|
2008-11-21 |
2014-03-03 |
Boehringer Ingelheim International Gmbh |
Composición farmacéutica de un potente inhibidor de HCV para su administración oral
|
US20100272674A1
(en)
|
2008-12-04 |
2010-10-28 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2747636A1
(en)
|
2008-12-19 |
2010-07-15 |
Gilead Sciences, Inc. |
Hcv ns3 protease inhibitors
|
US20100196321A1
(en)
|
2009-01-30 |
2010-08-05 |
Glaxosmithkline Llc |
Compounds
|
US8642544B2
(en)
|
2009-04-01 |
2014-02-04 |
Amylin Pharmaceuticals, Llc |
N-terminus conformationally constrained GLP-1 receptor agonist compounds
|
US8377962B2
(en)
|
2009-04-08 |
2013-02-19 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
BRPI1008103A2
(pt)
|
2009-04-24 |
2016-05-03 |
Cadila Healthcare Ltda |
" peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "
|
US20100297079A1
(en)
|
2009-05-20 |
2010-11-25 |
Chimerix, Inc. |
Compounds, compositions and methods for treating viral infection
|
EP2432318A4
(en)
|
2009-05-22 |
2012-11-21 |
Sequoia Pharmaceuticals Inc |
NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
|
US8232246B2
(en)
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
WO2011009961A1
(en)
*
|
2009-07-24 |
2011-01-27 |
Virologik Gmbh |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
NZ599133A
(en)
*
|
2009-09-15 |
2013-10-25 |
Taigen Biotechnology Co Ltd |
Hcv protease inhibitors
|
WO2011063502A1
(en)
|
2009-11-24 |
2011-06-03 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
EP2504343A4
(en)
|
2009-11-24 |
2013-04-17 |
Boehringer Ingelheim Int |
HEPATITIS C INHIBITOR COMPOUNDS
|
US20110178107A1
(en)
|
2010-01-20 |
2011-07-21 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|